We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

PerkinElmer Exhibits Automated Nucleic Acid Extraction Solutions at MEDLAB Middle East

By LabMedica International staff writers
Posted on 26 Jan 2022
Print article
Image: LabChip GX Touch Nucleic Acid Analyzer (Photo courtesy of PerkinElmer, Inc.)
Image: LabChip GX Touch Nucleic Acid Analyzer (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer, Inc. (Waltham, MA; USA) demonstrated its range of automated nucleic acid extraction solutions at the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre (DWTC) from January 24 to 27.

PerkinElmer demonstrated its high-throughput Vanadis NIPT solution which takes all the complexity out of cell-free DNA (cfDNA) testing, making it accessible to more women – and more cost-effective for laboratories. This breakthrough technology eliminates PCR amplification and gene sequencing, making it so easy to use that one laboratory technician can handle 2000 to 20,000 samples per year. Walkaway automation streamlines the process from primary tube to final results. Because the Vanadis system is an easy to use, non-NGS and non-PCR based method, any laboratory can use it. Also on display was the LabChip GX Touch nucleic acid analyzer with microfluidic technology that allows DNA and RNA quantitation and sizing to be done in seconds using automated capillary electrophoresis separation.

In addition, PerkinElmer highlighted the chemagic Prepito instrument which is based on the company’s proven technology for magnetic bead based DNA/RNA isolation and represents a top quality sample preparation system available as a compact benchtop instrument. The innovative instrument realizes cost effectiveness through automated dispensing of buffers into standard plastic devices instead of using expensive pre-filled cartridges. It includes barcode reading to provide comfort and to support highest quality assurance demands. Hands-on time is minimized and the processing time is as short as 30 minutes for up to 12 samples per batch.

PerkinElmer also displayed the VICTOR Nivo multimode microplate reader, now with Alpha technology, which packs all popular detection modes into the industry’s smallest multimode reader footprint. The perfect microplate reader for everyday biochemical and cell-based assays, it measures at any wavelength, with top and bottom reading of all standard technologies (top only reading for Alpha). Among other instruments, PerkinElmer exhibited the DELFIA Xpress platform which has been developed to streamline workflows in laboratories and clinics providing prenatal screening services. The platform offers a variety of benefits critical for operational efficiency, and with a wide range of available kits it supports different strategies in aneuploidy and pre-eclampsia screening.

Related Links:
PerkinElmer, Inc. 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.